Rochester, United States
Vyriad, a United States-based clinical-stage biotech company, is making strides in the biotechnology sector by pioneering targeted genetic therapies. These therapies are designed to deliver genes directly to cells using engineered viruses, viral vectors, and envelope glycoproteins. The company's technology is tailored for applications in oncolytic virotherapy, in vivo gene therapies, and gene editing.
The firm is actively engaged in Phase 1-2 clinical trials across a range of cancers, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, breast cancer, bladder cancer, and other types. Vyriad collaborates with industry leaders such as Regeneron and the Mayo Clinic, reinforcing its position in innovative cancer treatment research.
Since its founding in 2015, Vyriad has garnered significant investor interest, most recently securing a $25.00M Series B investment from Stine Seed Company in December 2025. This funding will likely accelerate its clinical development and collaborative efforts.
